Skip to main content
PMC home page
AAPS PharmSci logoLink to AAPS PharmSci
. 2002 Oct 29;4(4):193–205. doi: 10.1208/ps040440

An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine

Brendan M Johnson 1, William N Charman 1, Christopher J H Porter 1,✉
PMCID: PMC2751329  PMID: 12646011

Abstract

The potential inhibitory effects of 3 excipients (polyethylene glycol [PEG] 400, Pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate [TPGS]) on the P-glycoprotein (P-gp)-mediated efflux of digoxin (DIG) and cytochrome P450 3A (CYP3A)-mediated metabolism of verapamil (VRP) have been examined in an in vitro permeability model.

Experiments were conducted utilizing rat jejunal tissue mounted in diffusion chambers and included assessment of the serosal to mucosal (s to m) transport of DIG and the formation of norverapamil (NOR) during the mucosal to serosal transport of VRP, as measures of P-gp efflux and CYP3A metabolism, respectively.

The presence of PEG at 1%, 5%, and 20% (wt/vol) reduced both the s to m flux of DIG (by 47%, 57%, and 64%, respectively, when compared to control) and the metabolism of VRP (by 54%, 78%, and 100%) in a concentration-dependent manner. P85 (0.1% wt/vol) significantly reduced s to m DIG flux by 47% and inhibited VRP metabolism by 42%. TPGS had insignificant effects on both metabolism and efflux at a concentration of 0.01% (wt/vol). The P-gp inhibitory effects of PEG and P85 were evident regardless of whether the excipient was added to the mucosal side, the serosal side, or both sides of the tissue.

The current data suggest that inclusion of PEG and P85 as solubilizing agents during in vitro permeability assessment may have a significant impact on both drug metabolism and efflux processes. These compounds appear to exert their effects on P-gp primarily via direct transporter inhibition-or indirectly, through effects on buffer osmolarity, membrane fluidity, and/or mitochondrial toxicity and subsequent adenosine triphosphate (ATP) depletion.

Keywords: P-glycoprotein, CYP3A, intestinal, metabolism, permeability, PEG

References

  • 1.Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175:880–885. doi: 10.1016/0006-291X(91)91647-U. [DOI] [PubMed] [Google Scholar]
  • 2.Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46:27–43. doi: 10.1016/S0169-409X(00)00128-9. [DOI] [PubMed] [Google Scholar]
  • 3.Lennernäs H, Nylander S, Ungell AL. Jejunal permeability: a comparison between the Ussing chamber technique and the single-pass perfusion in humans. Pharm Res. 1997;14:667–671. doi: 10.1023/A:1012121632357. [DOI] [PubMed] [Google Scholar]
  • 4.Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735–7738. doi: 10.1073/pnas.84.21.7735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147–153. doi: 10.1172/JCI6663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998;286:1439–1445. [PubMed] [Google Scholar]
  • 7.Yamaguchi H, Yano I, Saito H, Inui KI. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther. 2002;300:1063–1069. doi: 10.1124/jpet.300.3.1063. [DOI] [PubMed] [Google Scholar]
  • 8.Spahn-Langguth H, Baktir G, Radschuweit A, et al. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as a model compound. Int J Clin Pharmacol Ther. 1998;36:16–24. [PubMed] [Google Scholar]
  • 9.Waziers I, Cugnec PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther. 1990;253:387–394. [PubMed] [Google Scholar]
  • 10.Richter O, Greiner B, Fromm MF, et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther. 2001;70:217–227. doi: 10.1067/mcp.2001.117937. [DOI] [PubMed] [Google Scholar]
  • 11.Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58:15–19. doi: 10.1016/0009-9236(95)90067-5. [DOI] [PubMed] [Google Scholar]
  • 12.Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99:2545–2553. doi: 10.1172/JCI119439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002;300:1036–1045. doi: 10.1124/jpet.300.3.1036. [DOI] [PubMed] [Google Scholar]
  • 14.Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  • 15.Nerukar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res. 1996;13:528–534. doi: 10.1023/A:1016033702220. [DOI] [PubMed] [Google Scholar]
  • 16.Mountfield RJ, Senepin S, Schleimer M, Walter I, Bittner B. Potential inhibitory effects of fomulation ingredients on intestinal cytochrome P450. Int J Pharm. 2000;211:89–92. doi: 10.1016/S0378-5173(00)00586-X. [DOI] [PubMed] [Google Scholar]
  • 17.Anderle P, Niederer E, Rubas W, et al. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci. 1998;87:757–762. doi: 10.1021/js970372e. [DOI] [PubMed] [Google Scholar]
  • 18.Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987;84:265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos. 1996;24:634–642. [PubMed] [Google Scholar]
  • 20.Taipalensuu J, Tömblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther. 2001;299:164–170. [PubMed] [Google Scholar]
  • 21.Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther. 2001;296:551–557. [PubMed] [Google Scholar]
  • 22.Yu L, Bridgers A, Polli J, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999;16:1812–1817. doi: 10.1023/A:1018939006780. [DOI] [PubMed] [Google Scholar]
  • 23.Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13:129–134. doi: 10.1002/mc.2940130302. [DOI] [PubMed] [Google Scholar]
  • 24.Johnson BM, Charman WN, Porter CJH. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J Pharm Pharmacol. 2001;53:1611–1619. doi: 10.1211/0022357011778214. [DOI] [PubMed] [Google Scholar]
  • 25.Saitoh H, Aungst BJ. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res. 1995;12:1304–1310. doi: 10.1023/A:1016217505990. [DOI] [PubMed] [Google Scholar]
  • 26.Batrakova EV, Han HY, Alakhov VY, Miller DW, Kabanov AV. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm Res. 1998;15:850–855. doi: 10.1023/A:1011964213024. [DOI] [PubMed] [Google Scholar]
  • 27.Nyberg L, Bratt L, Forsgren A, Hugosson S. Bioavailability of digoxin from tablets, I: in vitro characterization of digoxin tablets. Acta Pharm Suec. 1974;11:447–458. [PubMed] [Google Scholar]
  • 28.Petersen R, Flasch H, Heinz N. Darstellung und eigenschaften einiger glukuronide und sulfate von cardenoliden und cardenolidglykosider. Arzneimittelforschung. 1977;27:642–649. [PubMed] [Google Scholar]
  • 29.Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001;58:931–959. doi: 10.1007/PL00000912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MRP2 gene a good model of the intestinal mucosa? J Pharm Sci. 2002;19:773–779. doi: 10.1023/a:1016192413308. [DOI] [PubMed] [Google Scholar]
  • 31.Stephens RH, O'Neill CA, Warhurst A, Cartson GL, Rowland M, Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther. 2001;296:584–591. [PubMed] [Google Scholar]
  • 32.Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993;348:332–337. doi: 10.1007/BF00169164. [DOI] [PubMed] [Google Scholar]
  • 33.Batrakova EV, Han HY, Miller DW, Kabanov AV. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm Res. 1998;15:1525–1532. doi: 10.1023/A:1011942814300. [DOI] [PubMed] [Google Scholar]
  • 34.Pauli-Magnus C, Richter O, Burk O, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000;293:376–382. [PubMed] [Google Scholar]
  • 35.Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. Mechanism of Pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther. 2001;299:483–493. [PubMed] [Google Scholar]
  • 36.Batrakova EV, Li S, Alakhov VY, Kabanov AV. Selective energy depletion and sensitization of multiple drug resistant cancer cells by Pluronic block copolymers. Polym Prepr. 2000;41:1639–1640. [Google Scholar]
  • 37.Rapoport N, Marin AP, Timoshin AA. Effect of a polymeric surfactant on electron transport in HL-60 cells. Arch Biochem Biophys. 2000;384:100–108. doi: 10.1006/abbi.2000.2104. [DOI] [PubMed] [Google Scholar]
  • 38.Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem. 1999;259:18–24. doi: 10.1046/j.1432-1327.1999.00037.x. [DOI] [PubMed] [Google Scholar]
  • 39.Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane fluidity. Arch Biochem Biophys. 1995;319:309–315. doi: 10.1006/abbi.1995.1298. [DOI] [PubMed] [Google Scholar]
  • 40.Callaghan R, Stafford A, Epand RM. Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochim Biophys Acta. 1993;1175:277–282. doi: 10.1016/0167-4889(93)90217-D. [DOI] [PubMed] [Google Scholar]
  • 41.Krugliak P, Hollander D, Schlaepfer CC, Nguyen H, Ma TY. Mechanisms and sites of mannitol permeability of small and large intestine in the rat. Dig Dis Sci. 1994;39:796–801. doi: 10.1007/BF02087426. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSci are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES